Company has invested $150 million to build a 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina
Support for biologics manufacturability and Industry 4.0 initiatives
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
The next-gen logistics management solutions are making the global supply chains more customer-centric and sustainable
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
New line of Waters MaxPeak Premier columns further enhances the analysis by delivering 2x to 3x greater sensitivity than conventional steel columns
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
Subscribe To Our Newsletter & Stay Updated
